Suppr超能文献

非小细胞肺癌病理亚型的细胞组织学一致性:回顾性分析 602 例细针抽吸活检与 9 年随访手术标本,并分析未能确定亚型的相关因素

Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype.

机构信息

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

出版信息

Lung Cancer. 2012 Sep;77(3):501-6. doi: 10.1016/j.lungcan.2012.05.091. Epub 2012 May 31.

Abstract

BACKGROUND

The differential therapeutic efficacy and toxicity of targeted therapies has made subtyping of non-small lung cancer (NSCLC) mandatory. This study aimed to review the accuracy of NSCLC subtyping using lung fine needle aspirates (FNAs) in two periods (before and after the introduction of targeted therapy), checking the reasons for failure and the impact of the use of immunohistochemistry (IHC).

METHODS

An electronic search retrieved all NSCLC FNAs with a corresponding surgical specimen from 2001 to 2009. NSCLC, NOS (not otherwise specified) cases from 2005 to 2009 (after targeted therapy) were reviewed to determine reasons for failure in subtyping and to further subtype based solely on cytomorphology. The number of cases in which IHC was performed and the antibodies used were also recorded.

RESULTS

Cytohistological agreement of 602 lung FNAs (341 adenocarcinomas, 93 squamous cell carcinomas and 168 NSCLC, NOS) was achieved in 93.80%. There was a significant decrease in the percentage of cases not subtyped in the period after the introduction of targeted therapy (35.07% versus 24.57%). Final percentage of cases not subtyped after morphological review was 17.03%. IHC was performed in 157 cases, with an increased use in recent years. The number of antibodies did not influence the overall success in subtyping and an average of 3 markers was used. Most frequent antibodies used were TTF-1, CK7, high molecular weight keratin and p63. More than half of cases not subtyped even after IHC corresponded to poorly or undifferentiated neoplasms in the surgical specimens. For the NSCLC, NOS which IHC was not performed, a cell block was produced in 106 cases (75.71%). Review of the cell block slides from 2005 to 2009 showed that the majority (70.7%) had rare, few or no tumor cells.

CONCLUSIONS

Specific subtyping can be achieved in a high proportion of lung FNAs with high accuracy. The percentage of NSCLC, NOS has significantly decreased in recent years together with a trend for an increased use of IHC as well as increased number of cell blocks produced. An average of 3 IHC markers was used for subtyping and the number of markers did not influence the overall subtyping.

摘要

背景

靶向治疗的疗效和毒性存在差异,因此有必要对非小细胞肺癌(NSCLC)进行亚型分类。本研究旨在回顾使用肺细针抽吸(FNA)在两个时期(靶向治疗前和靶向治疗后)对 NSCLC 进行亚型分类的准确性,检查分类失败的原因以及免疫组织化学(IHC)的使用对其的影响。

方法

电子检索了 2001 年至 2009 年所有有相应手术标本的 NSCLC FNA。对 2005 年至 2009 年(靶向治疗后)的 NSCLC、NOS(非特指型)病例进行了回顾性研究,以确定分类失败的原因,并根据细胞学形态进一步进行分类。还记录了进行 IHC 的病例数量和使用的抗体。

结果

602 例肺 FNA(341 例腺癌、93 例鳞状细胞癌和 168 例 NSCLC、NOS)的细胞组织学符合率为 93.80%。在引入靶向治疗后,未进行亚型分类的病例百分比显著下降(35.07%比 24.57%)。经过形态学检查后,最终未分类的病例百分比为 17.03%。157 例进行了 IHC,近年来使用有所增加。抗体数量对分类总体成功率没有影响,平均使用了 3 种标志物。最常使用的抗体是 TTF-1、CK7、高分子量角蛋白和 p63。即使在 IHC 后,仍有超过一半的未分类病例在手术标本中对应为低分化或未分化肿瘤。对于未进行 IHC 的 NSCLC、NOS,106 例(75.71%)制作了细胞块。对 2005 年至 2009 年的细胞块切片进行回顾性研究发现,大多数(70.7%)仅有少量、少量或无肿瘤细胞。

结论

高比例的肺 FNA 可以实现特定的亚型分类,具有很高的准确性。近年来,NSCLC、NOS 的比例显著下降,IHC 的使用趋势增加,制作的细胞块数量也增加。平均使用 3 种 IHC 标志物进行分类,并且标志物数量不影响总体分类。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验